Testing a treatment schedule for metastatic Ewing sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new schedule of standard chemotherapy drugs to see if it improves outcomes for people with metastatic Ewing sarcoma or CIC-rearranged sarcoma. It is for patients who have not had prior cancer treatment, except possibly one initial cycle of VDC.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 1 year (no upper age limit).
- You have been diagnosed with Ewing sarcoma that has spread, or with CIC-rearranged sarcoma that has spread.
- You have not received any previous cancer treatment, except possibly one cycle of VDC (vincristine, doxorubicin, cyclophosphamide).
- You have enough tumor tissue available for testing (fresh frozen or preserved slides).
- You are healthy enough for the treatment, in your doctor's opinion.
- If you could become pregnant or father a child, you agree to use two birth control methods or not have sex during and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different chemo combinations for Ewing's sarcoma that has not responded to first-line treatment. One group gets a special liposomal form of irinotecan plus temozolomide and vincristine; the other gets standard irinotecan with the same two drugs. The goal is to see which is safer and more effective.
This trial tests new drugs for young people with Ewing sarcoma or similar sarcomas that have come back or not responded to standard treatment. The goal is to see if these drugs can shrink or control the cancer.
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and fluzoparib) for people with Ewing sarcoma that has spread or come back after first treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a drug called eflornithine (DFMO) for people with Ewing sarcoma or osteosarcoma that has come back or spread. The goal is to see if DFMO can help control the cancer after standard treatment.
This trial tests an experimental drug, KC1036, for adolescents with advanced Ewing sarcoma that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow the cancer.
This trial tests a personalized radiation therapy that adjusts the dose based on your tumor. It aims to improve treatment for Ewing sarcoma while limiting side effects.
Hear when a new Metastatic Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.